Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 6Uterine Cervical Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Castration-resistant Prostate Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 20Gemcitabine 18Cisplatin 14Magnetic Resonance Spectroscopy 13enfortumab vedotin 12Specimen Handling 10Cystectomy 10Docetaxel 8Mitomycin 7Standard of Care 6Cystoscopy 6Transurethral Resection of Bladder 5Radiotherapy 5Carboplatin 5durvalumab 4Practice Guidelines as Topic 4Nivolumab 4Radiation 3Multiparametric Magnetic Resonance Imaging 3Mitozytrex 3Fluorouracil 3tislelizumab 2dehydroftorafur 2cemiplimab 2avelumab 2alvimopan 2Therapeutics 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urinary Bladder Neoplasms × disitamab vedotin × Clear all
NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Seagen Inc.

Phase 2 Recruiting
372 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡